Ozge Yilmaz Topal
Research Subjects
Research Interests
Ozge Yilmaz Topal has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Emine Dibek Mısırlıoğlu
Department of Pediatric Allergy/Immunology, Ankara Bilkent City Hospital, University of Health Sciences, Ankara, Türkiye
5 shared publications Muge Toyran
Division of Pediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
4 shared publications- Muge Toyran
Ankara Hematology Onkology Children’s Training and Research Hospital, Pediatric Allergy, Ankara, Turkey
4 shared publications Betul Karaatmaca
Division of Pediatric Allergy and Immunology, Ankara City Hospital, Ankara, Turkey
3 shared publications- Betül Karaatmaca
Department of Pediatric Allergy/Immunology Ankara Bilkent City Hospital Ankara Turkey
3 shared publications Ersoy Civelek
Division of Pediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
3 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 53 (6) , 7-13
Determining specific IgE cutoff values to predict reactions in oral food challenges for cow’s milk allergy using the Immulite System
The diagnosis of IgE-mediated cow’s milk allergy (CMA) involves serum-specific IgE (spIgE), skin prick tests (SPT), and the gold standard oral food challenge (OFC). SpIgE levels are measured using methods such as ImmunoCAP and IMMULITE, with most cutoff data derived from ImmunoCAP. This study aims to determine IMMULITE-specific cutoff values to predict OFC positivity. Patients diagnosed with CMA via OFC between 2019 and 2023 were retrospectively analyzed. Data on demographics, eosinophil counts, total and specific IgE levels, and SPT results were collected. OFC was conducted using yogurt, milk-based formula, or milk-containing muffins. SPTs were performed with commercial extracts (Lofarma®) and pasteurized milk using the prick-to-prick method. SpIgE levels were measured with the Siemens® IMMULITE 2000 Immunoassay System, with values ≥0.35 kU/L considered positive. The study included 50 OFC-positive patients (60% males) and 50 age- and clinically matched controls without objective OFC reactions. The median age at diagnosis was 6 months (IQR: 3–21), and 52% presented with atopic dermatitis. OFC reactions occurred with yogurt in 42 patients (84%), muffins in 6, and milk in 2; 26% of reactions were anaphylaxis. IMMULITE-derived cutoff values were 3.13 kU/L (AUC: 0.776, 72% sensitivity, 72% specificity) for cow’s milk spIgE and 1.85 kU/L for casein. SPT enduration cutoffs were 4.25 mm for pasteurized milk and 3.5 mm for commercial extracts. This study provides critical IMMULITE-specific spIgE cutoffs to predict OFC outcomes, offering valuable reference ranges for clinical CMA diagnosis.
- 1 November 2025
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 53 (6) , 7-13
Open AccessDetermining specific IgE cutoff values to predict reactions in oral food challenges for cow’s milk allergy using the Immulite System
The diagnosis of IgE-mediated cow’s milk allergy (CMA) involves serum-specific IgE (spIgE), skin prick tests (SPT), and the gold standard oral food challenge (OFC). SpIgE levels are measured using methods such as ImmunoCAP and IMMULITE, with most cutoff data derived from ImmunoCAP. This study aims to determine IMMULITE-specific cutoff values to predict OFC positivity. Patients diagnosed with CMA via OFC between 2019 and 2023 were retrospectively analyzed. Data on demographics, eosinophil counts, total and specific IgE levels, and SPT results were collected. OFC was conducted using yogurt, milk-based formula, or milk-containing muffins. SPTs were performed with commercial extracts (Lofarma®) and pasteurized milk using the prick-to-prick method. SpIgE levels were measured with the Siemens® IMMULITE 2000 Immunoassay System, with values ≥0.35 kU/L considered positive. The study included 50 OFC-positive patients (60% males) and 50 age- and clinically matched controls without objective OFC reactions. The median age at diagnosis was 6 months (IQR: 3–21), and 52% presented with atopic dermatitis. OFC reactions occurred with yogurt in 42 patients (84%), muffins in 6, and milk in 2; 26% of reactions were anaphylaxis. IMMULITE-derived cutoff values were 3.13 kU/L (AUC: 0.776, 72% sensitivity, 72% specificity) for cow’s milk spIgE and 1.85 kU/L for casein. SPT enduration cutoffs were 4.25 mm for pasteurized milk and 3.5 mm for commercial extracts. This study provides critical IMMULITE-specific spIgE cutoffs to predict OFC outcomes, offering valuable reference ranges for clinical CMA diagnosis.
- Open Access
- 1 July 2025
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (7) , e70103
Clinical diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in children: An EAACI position paper
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but severe cutaneous adverse drug reaction encountered in both adults and children with a significant mortality rate. A number of guidelines or consensus reports have been published for optimal diagnosis and treatment of DRESS in adults, but none specifically for children. It is increasingly evident that there are significant differences in drug pharmacokinetics, metabolism, co‐occurring infections, comorbidities, clinical manifestations, and severity of drug allergies between children and adults, as well as across different pediatric age groups. Aim: This position paper aimed to evaluate and compare all the available data related to clinical features, diagnosis, and treatment of DRESS in adults and children in an attempt to identify the differences and gaps, and produce recommendations on diagnosis and treatment of this fatal disorder in children. Materials and Methods: A search of MEDLINE (via PubMed) and Web of Science from 2000 to 2024, including studies that assessed children with DRESS syndrome, was performed. In the absence of pediatric‐specific data, studies involving adults or mixed populations (both adults and children) were also analyzed. Among a total of retrieved 5264 records, following duplicate removal and full‐text assessment, a total of 493 manuscripts related to DRESS were included in the report and recommendation generation. The recommendations for the clinical diagnosis and treatment of DRESS in children were formulated in accordance with the directionality and strength guidelines suggested by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group and related research. Results: Among retrieved records, there was only one randomized controlled trial, one meta‐analysis, one systematic review, six retrospective comparative studies on treatment, and one systematic review on the accuracy of skin tests in DRESS. All of these studies were conducted in adults, rarely involving children, and none were exclusively performed in pediatric populations. Comparison of systematic case reviews revealed that some aspects of clinical features, prognosis, and mortality in children differed from those in adults. The diagnosis of DRESS is based on several clinical and laboratory criteria, which have been developed for adult patients but have not been validated for children. Causality assessment tools, in vivo skin tests, and in vitro tests have been used widely in adults to identify the culprit drugs in DRESS, while these tools are more rarely employed or reported in children. Adult guidelines or consensus reports recommend a severity‐based, stepwise treatment approach for DRESS, whereas no such severity classification or treatment algorithms exist exclusively for children, leading to inconsistent management with numerous instances of overtreatment and undertreatment. Conclusion: There is very limited evidence‐based data on the diagnosis and management of DRESS both in adults and in children. Until more evidence becomes available, we propose a diagnostic algorithm, a DRESS severity classification, and a severity‐based tailored treatment approach, all adapted to pediatric needs together with issued recommendations to enable physicians to provide better care and reduce morbidity and mortality in pediatric patients.
- 1 July 2025
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (7) , e70103
Open AccessClinical diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in children: An EAACI position paper
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but severe cutaneous adverse drug reaction encountered in both adults and children with a significant mortality rate. A number of guidelines or consensus reports have been published for optimal diagnosis and treatment of DRESS in adults, but none specifically for children. It is increasingly evident that there are significant differences in drug pharmacokinetics, metabolism, co‐occurring infections, comorbidities, clinical manifestations, and severity of drug allergies between children and adults, as well as across different pediatric age groups. Aim: This position paper aimed to evaluate and compare all the available data related to clinical features, diagnosis, and treatment of DRESS in adults and children in an attempt to identify the differences and gaps, and produce recommendations on diagnosis and treatment of this fatal disorder in children. Materials and Methods: A search of MEDLINE (via PubMed) and Web of Science from 2000 to 2024, including studies that assessed children with DRESS syndrome, was performed. In the absence of pediatric‐specific data, studies involving adults or mixed populations (both adults and children) were also analyzed. Among a total of retrieved 5264 records, following duplicate removal and full‐text assessment, a total of 493 manuscripts related to DRESS were included in the report and recommendation generation. The recommendations for the clinical diagnosis and treatment of DRESS in children were formulated in accordance with the directionality and strength guidelines suggested by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group and related research. Results: Among retrieved records, there was only one randomized controlled trial, one meta‐analysis, one systematic review, six retrospective comparative studies on treatment, and one systematic review on the accuracy of skin tests in DRESS. All of these studies were conducted in adults, rarely involving children, and none were exclusively performed in pediatric populations. Comparison of systematic case reviews revealed that some aspects of clinical features, prognosis, and mortality in children differed from those in adults. The diagnosis of DRESS is based on several clinical and laboratory criteria, which have been developed for adult patients but have not been validated for children. Causality assessment tools, in vivo skin tests, and in vitro tests have been used widely in adults to identify the culprit drugs in DRESS, while these tools are more rarely employed or reported in children. Adult guidelines or consensus reports recommend a severity‐based, stepwise treatment approach for DRESS, whereas no such severity classification or treatment algorithms exist exclusively for children, leading to inconsistent management with numerous instances of overtreatment and undertreatment. Conclusion: There is very limited evidence‐based data on the diagnosis and management of DRESS both in adults and in children. Until more evidence becomes available, we propose a diagnostic algorithm, a DRESS severity classification, and a severity‐based tailored treatment approach, all adapted to pediatric needs together with issued recommendations to enable physicians to provide better care and reduce morbidity and mortality in pediatric patients.
- 8 May 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (5) , 416-422
Development of respiratory allergic diseases according to cow’s milk protein allergy mechanisms
Cow's milk protein allergy (CMPA) is early life's most common food allergy. There is limited data on the development of respiratory allergies in childhood for infants with CMPA. This study aimed to evaluate the development of respiratory allergic diseases in childhood according to the mechanism of CMPA in patients with CMPA in the first two years of life. Patients who were diagnosed with CMPA in the first two years of life and were over five years old during the study period were included in the study. The sociodemographic, clinical, and laboratory data of patients were recorded, and the status of respiratory allergic disease development in patients was assessed using the ISAAC questionnaire. A total of 301 patients were included in the study; 182 (60.5%) were male. Most of the patients had mixed-type (87;28.9%) and had non-IgE-mediated (n:87;28.9%) CMPA. Of CMPA cases, 27.9% developed doctor-diagnosed asthma and 31.2% developed doctor-diagnosed allergic rhinitis. Doctor-diagnosed asthma was observed mostly with IgE-mediated CMPA (n:30;37%), and doctor-diagnosed allergic rhinitis was observed mostly with non-IgE-mediated CMPA (n:32;36.8%), and these differences were not statistically significant (p = 0.094, p = 0.385). Also, maternal asthma increased the risk of doctor-diagnosed asthma, while parental consanguinity, allergic rhinitis in mother/sibling, and paternal eczema were risk factors for doctor-diagnosed allergic rhinitis. In this study, 27.9% of patients with CMPA in the first two years of life developed doctor-diagnosed asthma, and 31.2% developed allergic rhinitis. There was no difference in the frequency of occurrence based on the mechanism of CMPA development.
- 8 May 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (5) , 416-422
Development of respiratory allergic diseases according to cow’s milk protein allergy mechanisms
Cow's milk protein allergy (CMPA) is early life's most common food allergy. There is limited data on the development of respiratory allergies in childhood for infants with CMPA. This study aimed to evaluate the development of respiratory allergic diseases in childhood according to the mechanism of CMPA in patients with CMPA in the first two years of life. Patients who were diagnosed with CMPA in the first two years of life and were over five years old during the study period were included in the study. The sociodemographic, clinical, and laboratory data of patients were recorded, and the status of respiratory allergic disease development in patients was assessed using the ISAAC questionnaire. A total of 301 patients were included in the study; 182 (60.5%) were male. Most of the patients had mixed-type (87;28.9%) and had non-IgE-mediated (n:87;28.9%) CMPA. Of CMPA cases, 27.9% developed doctor-diagnosed asthma and 31.2% developed doctor-diagnosed allergic rhinitis. Doctor-diagnosed asthma was observed mostly with IgE-mediated CMPA (n:30;37%), and doctor-diagnosed allergic rhinitis was observed mostly with non-IgE-mediated CMPA (n:32;36.8%), and these differences were not statistically significant (p = 0.094, p = 0.385). Also, maternal asthma increased the risk of doctor-diagnosed asthma, while parental consanguinity, allergic rhinitis in mother/sibling, and paternal eczema were risk factors for doctor-diagnosed allergic rhinitis. In this study, 27.9% of patients with CMPA in the first two years of life developed doctor-diagnosed asthma, and 31.2% developed allergic rhinitis. There was no difference in the frequency of occurrence based on the mechanism of CMPA development.
- Open Access
- 18 April 2025
- Published by Wiley
CLINICAL DIAGNOSIS AND MANAGEMENT OF DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS(DRESS) IN CHILDREN: AN EAACI POSITION PAPER
Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a rare but severe cutaneous adverse drug reaction (SCAR) which presents by both skin and systemic symptoms and a significant mortality rate. The clinical features and prognosis in children differ markedly from those in adults. The diagnosis of DRESS is based on several clinical and laboratory criteria, which have been developed for adult patients but have not been validated for children. Differential diagnosis is both important and challenging in children due to the potential mimicry of a wide range of diseases, particularly viral infections. Causality assessment tools, in vivo skin tests, and in vitro tests have been used to identify the culprit drugs in DRESS, with low to moderate sensitivity in adults. However, these tools are more rarely employed or reported in children. Adult guidelines or consensus reports recommend a severity-based, stepwise treatment approach for DRESS, whereas no such severity classification or treatment algorithms exist for children, leading to inconsistent management with numerous instances of overtreatment and undertreatment. This EAACI Task Force on paediatric SCARs has developed a severity classification and a treatment strategy based on this classification, along with recommendations for the diagnosis and treatment of DRESS in children.
- 18 April 2025
- Published by Wiley
Open AccessCLINICAL DIAGNOSIS AND MANAGEMENT OF DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS(DRESS) IN CHILDREN: AN EAACI POSITION PAPER
Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a rare but severe cutaneous adverse drug reaction (SCAR) which presents by both skin and systemic symptoms and a significant mortality rate. The clinical features and prognosis in children differ markedly from those in adults. The diagnosis of DRESS is based on several clinical and laboratory criteria, which have been developed for adult patients but have not been validated for children. Differential diagnosis is both important and challenging in children due to the potential mimicry of a wide range of diseases, particularly viral infections. Causality assessment tools, in vivo skin tests, and in vitro tests have been used to identify the culprit drugs in DRESS, with low to moderate sensitivity in adults. However, these tools are more rarely employed or reported in children. Adult guidelines or consensus reports recommend a severity-based, stepwise treatment approach for DRESS, whereas no such severity classification or treatment algorithms exist for children, leading to inconsistent management with numerous instances of overtreatment and undertreatment. This EAACI Task Force on paediatric SCARs has developed a severity classification and a treatment strategy based on this classification, along with recommendations for the diagnosis and treatment of DRESS in children.
- Open Access
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (1) , 316-323
Evaluation of accompanying allergic disease in children with proven drug allergies
Data on the prevalence of allergic diseases in children with proven drug allergies are limited. We aim to evaluate thefrequency of allergic comorbidity in children with proven common drug allergies.Materials and methods: Children with drug hypersensitivity confirmed by diagnostic allergy tests at our center between January 2010and December 2020 were screened retrospectively. Patients with the most common drug allergies (due to antibiotics, nonsteroidalantiinflammatory drugs [NSAIDs], and antiepileptic drugs) were selected for analysis. Age, sex, the culprit drug, initial reactioncharacteristics, diagnostic test results, and the study physician who diagnosed concomitant allergic diseases were noted.Results: A total of 168 patients (boys, 51.2%) with a median age of 12 years (IQR = 8–16.3) were included in the study. The culprit drugwas an antibiotic in 63% (n = 106), NSAID in 25% (n = 42) and anticonvulsant in 11.9 % (n = 20) of the patients. Drug hypersensitivityreactions were immediate in 74.4 % (n = 125) and delayed in 25.6 % (n = 43) of the patients. Seventy-five patients (44.6 %) had at leastone allergic disease, most commonly rhinitis (27.3 %, n = 46) or asthma (25 %, n = 42). Fifty-five patients underwent skin prick testswith aeroallergens, producing a positive result in 60% (n = 31). The prevalence of allergic disease was not differing according to theculprit drug. The frequency of developing at least one concomitant allergic disease was 47.2% (n = 50/106) for antibiotic hypersensitivity,52.4% (n = 22/42) for NSAID hypersensitivity, and 15% (n = 3/20) for anticonvulsant hypersensitivity (p < 0.00).Immediate drug hypersensitivity reactions were more frequent in children who had allergic diseases (80 % vs. 64.5 %; p = 0.027).Conclusion: Nearly half (44.6%) of the children with proven drug hypersensitivity had concomitant allergic diseases and immediatereactions were more common in this group. Children evaluated for drug hypersensitivity should be assessed for other allergic diseases.
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (1) , 316-323
Open AccessEvaluation of accompanying allergic disease in children with proven drug allergies
Data on the prevalence of allergic diseases in children with proven drug allergies are limited. We aim to evaluate thefrequency of allergic comorbidity in children with proven common drug allergies.Materials and methods: Children with drug hypersensitivity confirmed by diagnostic allergy tests at our center between January 2010and December 2020 were screened retrospectively. Patients with the most common drug allergies (due to antibiotics, nonsteroidalantiinflammatory drugs [NSAIDs], and antiepileptic drugs) were selected for analysis. Age, sex, the culprit drug, initial reactioncharacteristics, diagnostic test results, and the study physician who diagnosed concomitant allergic diseases were noted.Results: A total of 168 patients (boys, 51.2%) with a median age of 12 years (IQR = 8–16.3) were included in the study. The culprit drugwas an antibiotic in 63% (n = 106), NSAID in 25% (n = 42) and anticonvulsant in 11.9 % (n = 20) of the patients. Drug hypersensitivityreactions were immediate in 74.4 % (n = 125) and delayed in 25.6 % (n = 43) of the patients. Seventy-five patients (44.6 %) had at leastone allergic disease, most commonly rhinitis (27.3 %, n = 46) or asthma (25 %, n = 42). Fifty-five patients underwent skin prick testswith aeroallergens, producing a positive result in 60% (n = 31). The prevalence of allergic disease was not differing according to theculprit drug. The frequency of developing at least one concomitant allergic disease was 47.2% (n = 50/106) for antibiotic hypersensitivity,52.4% (n = 22/42) for NSAID hypersensitivity, and 15% (n = 3/20) for anticonvulsant hypersensitivity (p < 0.00).Immediate drug hypersensitivity reactions were more frequent in children who had allergic diseases (80 % vs. 64.5 %; p = 0.027).Conclusion: Nearly half (44.6%) of the children with proven drug hypersensitivity had concomitant allergic diseases and immediatereactions were more common in this group. Children evaluated for drug hypersensitivity should be assessed for other allergic diseases.
- Open Access
- 29 May 2023
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 17 (3) , 227-232
Evaluation of Chronic Cough Etiologies in Children
Objective: Cough is one of the leading causes of hospitalization in children worldwide. It should be considered important because it can be a symptom of various serious diseases and affects the quality of life of the child. A differential diagnosis should be performed on all children with a chronic cough. This study aimed to determine the etiologies in patients evaluated for chronic cough. Material and Methods: The study included patients admitted to the pediatric immunology and allergy outpatient clinic, with the complaint of chronic cough between the ages of 0–18 years. Clinical and demographic characteristics of patients were recorded. Results: This study included 323 patients between the ages of 0-18years. The median age of the patients was 7 (interquartile range: 5-9.7) years. One hundred and forty five (45%) of the patients were female. One hundred seventy-nine (55.4%) patients had a family history of atopic diseases such as asthma and/or allergic rhinitis. The presence of aeroallergen sensitivity was demonstrated in 127 patients. One hundred and forty-four (44.6%) patients were diagnosed with asthma, 75 (23.2%) patients with wheezing, 54 (16.7%) patients with post-infectious cough, 43 (13.3%) patients with postnasal drip syndrome, 4 (1.2%) patients with gastroesophageal reflux, 2 (0.6%) patients with foreign body aspiration, and 1 (0.3%) patient with psychogenic cough. Moreover, two patients with asthma, and one patient with wheezing had reflux symptoms in addition to the diagnosis of asthma and wheezing. One patient was found to have a partial IgA deficiency, and 18 patients had hypogammaglobulinemia. Immunoglobulin replacement therapy was initiated for a patient with hypogammaglobulinemia. Of the 219 patients diagnosed with asthma or wheezing, 144 had an atopic disease in the family (p<0.001). It was found that one hundred and eighty-five patients (57.3%) had domestic smoke exposure. Furthermore, smoke exposure was observed in 58 (77.3%) of 75 patients under the age of 6 years who were followed up with the diagnosis of wheezing (p= 0.010). Conclusion: In our study, asthma, which is one of the most common causes of chronic cough in the literature, was found to be the most common cause. For a correct approach when making a differential diagnosis in pediatric patients presenting with chronic cough, the patient’s history, physical examination, laboratory tests, and risk factors should be evaluated as a whole with systematic evaluation.
- 29 May 2023
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 17 (3) , 227-232
Open AccessEvaluation of Chronic Cough Etiologies in Children
Objective: Cough is one of the leading causes of hospitalization in children worldwide. It should be considered important because it can be a symptom of various serious diseases and affects the quality of life of the child. A differential diagnosis should be performed on all children with a chronic cough. This study aimed to determine the etiologies in patients evaluated for chronic cough. Material and Methods: The study included patients admitted to the pediatric immunology and allergy outpatient clinic, with the complaint of chronic cough between the ages of 0–18 years. Clinical and demographic characteristics of patients were recorded. Results: This study included 323 patients between the ages of 0-18years. The median age of the patients was 7 (interquartile range: 5-9.7) years. One hundred and forty five (45%) of the patients were female. One hundred seventy-nine (55.4%) patients had a family history of atopic diseases such as asthma and/or allergic rhinitis. The presence of aeroallergen sensitivity was demonstrated in 127 patients. One hundred and forty-four (44.6%) patients were diagnosed with asthma, 75 (23.2%) patients with wheezing, 54 (16.7%) patients with post-infectious cough, 43 (13.3%) patients with postnasal drip syndrome, 4 (1.2%) patients with gastroesophageal reflux, 2 (0.6%) patients with foreign body aspiration, and 1 (0.3%) patient with psychogenic cough. Moreover, two patients with asthma, and one patient with wheezing had reflux symptoms in addition to the diagnosis of asthma and wheezing. One patient was found to have a partial IgA deficiency, and 18 patients had hypogammaglobulinemia. Immunoglobulin replacement therapy was initiated for a patient with hypogammaglobulinemia. Of the 219 patients diagnosed with asthma or wheezing, 144 had an atopic disease in the family (p<0.001). It was found that one hundred and eighty-five patients (57.3%) had domestic smoke exposure. Furthermore, smoke exposure was observed in 58 (77.3%) of 75 patients under the age of 6 years who were followed up with the diagnosis of wheezing (p= 0.010). Conclusion: In our study, asthma, which is one of the most common causes of chronic cough in the literature, was found to be the most common cause. For a correct approach when making a differential diagnosis in pediatric patients presenting with chronic cough, the patient’s history, physical examination, laboratory tests, and risk factors should be evaluated as a whole with systematic evaluation.
- 16 June 2022
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 35 (2) , 58-64
Psychological Distress and Drug Provocation Test-Related Anxiety Levels of Pediatric Patients and Their Parents
Background: Drug provocation tests (DPTs) are the gold standard for the diagnosis of drug hypersensitivity reaction (DHR). To the best of our knowledge, there is no previous study reporting DPT-related anxiety levels in children and their parents. This study aimed to determine the difference in pre- and post-DPT anxiety levels of parents and children who were informed of the possibility of another DHR during the DPT, and to evaluate the relationship between parental psychological distress and anxiety levels. Methods: The study included children who underwent DPT in our clinic between July 1, 2019, and February 29, 2020, and accompanying parents who consented to participate. Age-appropriate State-Trait Anxiety Inventory scales were used to assess levels of state and trait anxiety in the patients and parents. The Symptom Checklist-90-Revised (SCL-90-R) was used to screen for psychological symptoms in parents. Results: Data were collected from the parents of 69 children who underwent DPTs. The patients' median age was 7.28 (interquartile range: 4.52–10.06) and their parents' mean age was 35.28 ± 5.38 years. Anxiety-related data were collected from 21 pediatric patients. The children and parents had higher state anxiety scores before DPT compared to after DPT. There was a positive correlation between the parents' trait anxiety and pre-DPT state anxiety scores. In addition, parental pre-DPT state anxiety scores were positively correlated with SCL-90-R general severity index, somatization, anxiety, obsessive-compulsive, and depression subscale scores. Conclusion: The risk of allergic reaction in DPT may cause anxiety. A high level of parental anxiety before DPT, which gradually decreased after negative test results, was associated with history of drug-induced anaphylaxis in their children and high trait anxiety. Appropriate evaluation of patients and parents before DPT and providing detailed information may be important to reduce this anxiety.
- 16 June 2022
- Published by SAGE Publications in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 35 (2) , 58-64
Psychological Distress and Drug Provocation Test-Related Anxiety Levels of Pediatric Patients and Their Parents
Background: Drug provocation tests (DPTs) are the gold standard for the diagnosis of drug hypersensitivity reaction (DHR). To the best of our knowledge, there is no previous study reporting DPT-related anxiety levels in children and their parents. This study aimed to determine the difference in pre- and post-DPT anxiety levels of parents and children who were informed of the possibility of another DHR during the DPT, and to evaluate the relationship between parental psychological distress and anxiety levels. Methods: The study included children who underwent DPT in our clinic between July 1, 2019, and February 29, 2020, and accompanying parents who consented to participate. Age-appropriate State-Trait Anxiety Inventory scales were used to assess levels of state and trait anxiety in the patients and parents. The Symptom Checklist-90-Revised (SCL-90-R) was used to screen for psychological symptoms in parents. Results: Data were collected from the parents of 69 children who underwent DPTs. The patients' median age was 7.28 (interquartile range: 4.52–10.06) and their parents' mean age was 35.28 ± 5.38 years. Anxiety-related data were collected from 21 pediatric patients. The children and parents had higher state anxiety scores before DPT compared to after DPT. There was a positive correlation between the parents' trait anxiety and pre-DPT state anxiety scores. In addition, parental pre-DPT state anxiety scores were positively correlated with SCL-90-R general severity index, somatization, anxiety, obsessive-compulsive, and depression subscale scores. Conclusion: The risk of allergic reaction in DPT may cause anxiety. A high level of parental anxiety before DPT, which gradually decreased after negative test results, was associated with history of drug-induced anaphylaxis in their children and high trait anxiety. Appropriate evaluation of patients and parents before DPT and providing detailed information may be important to reduce this anxiety.
- 14 December 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (1) , e13708
Successful clofarabine desensitization in a pediatric patient with acute myeloid leukemia
- 14 December 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (1) , e13708
Successful clofarabine desensitization in a pediatric patient with acute myeloid leukemia
- 25 October 2021
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 63 (5) , 801-810
Anxiety among the parents of pediatric patients receiving IVIG therapy during the Covid-19 pandemic
Background. Symptomatic COVID-19 cases in children occur mostly in those with primary immunodeficiency (PID), chronic lung diseases, and heart disease. Guidelines recommend that patients with PID continue to use their regular medication during the pandemic. Objectives. This study aimed to evaluate anxiety related to COVID-19 in the parents of patients receiving intravenous immunoglobulin (IVIG) treatment in our hospital and to evaluate the effect of their anxiety on the continuity of treatment. Methods. The parents of the patients who underwent IVIG therapy in our clinic during the pandemic (between May 15, 2020 and July 1, 2020) were included in our study. Results. Twenty-seven patients with PID whose IVIG therapy was initiated before the pandemic and 29 non- PID control subjects were included in the study. All patients received IVIG treatment in our clinic continued treatment during the pandemic at the same dose intervals. Parents in the IVIG group had significantly higher state (p=0.003) and trait (p=0.003) anxiety scores compared to control parents. IVIG group showed statistically significant higher scores in Beck depression inventory, than the control group (p=0.002). Conclusions. The parents of PID patients who needed to come to the hospital for IVIG therapy had higher anxiety levels than the parents of similar aged children who presented to our clinic for different complaints between the same dates. Despite their concerns, the parents of all patients under IVIG therapy maintained treatment continuity at the recommended treatment intervals. None of our immunodeficient patients who presented for treatment during the pandemic contracted COVID-19 infection during our study.
- 25 October 2021
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 63 (5) , 801-810
Anxiety among the parents of pediatric patients receiving IVIG therapy during the Covid-19 pandemic
Background. Symptomatic COVID-19 cases in children occur mostly in those with primary immunodeficiency (PID), chronic lung diseases, and heart disease. Guidelines recommend that patients with PID continue to use their regular medication during the pandemic. Objectives. This study aimed to evaluate anxiety related to COVID-19 in the parents of patients receiving intravenous immunoglobulin (IVIG) treatment in our hospital and to evaluate the effect of their anxiety on the continuity of treatment. Methods. The parents of the patients who underwent IVIG therapy in our clinic during the pandemic (between May 15, 2020 and July 1, 2020) were included in our study. Results. Twenty-seven patients with PID whose IVIG therapy was initiated before the pandemic and 29 non- PID control subjects were included in the study. All patients received IVIG treatment in our clinic continued treatment during the pandemic at the same dose intervals. Parents in the IVIG group had significantly higher state (p=0.003) and trait (p=0.003) anxiety scores compared to control parents. IVIG group showed statistically significant higher scores in Beck depression inventory, than the control group (p=0.002). Conclusions. The parents of PID patients who needed to come to the hospital for IVIG therapy had higher anxiety levels than the parents of similar aged children who presented to our clinic for different complaints between the same dates. Despite their concerns, the parents of all patients under IVIG therapy maintained treatment continuity at the recommended treatment intervals. None of our immunodeficient patients who presented for treatment during the pandemic contracted COVID-19 infection during our study.
- Open Access
- 24 September 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (1) , e13661
Clinical characteristics of COVID‐19 in children and young adolescents with inborn errors of immunity
- 24 September 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (1) , e13661
Open AccessClinical characteristics of COVID‐19 in children and young adolescents with inborn errors of immunity